The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.
Searles
Gordon
G
Keystone Dermatology Institute, Edmonton, AB. gesearles@mac.com
Bissonnette
Robert
R
Landells
Ian
I
Shear
Neil H
NH
D000077944:Alefacept; D002170:Canada / Q000453:epidemiology; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D009017:Morbidity / Q000639:trends; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012042:Registries; D016896:Treatment Outcome
D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept